1-3 of 3
Julie Niolat
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Jordi Esteve, Aristoteles Giagounidis, Hee-Je Kim, MD, PhD, Yasushi Miyazaki, MD PhD, Uwe Platzbecker, Andre C. Schuh, Mikkael A. Sekeres, Jörg Westermann, Zhijian Xiao, Kamel Malek, Jeffrey Scott, Julie Niolat, Severine Peyrard, Fei Ma, Flavia Kiertsman, Mario Stegert, Sabine Hertle, Pierre Fenaux, MD PhD, Valeria Santini
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-134718
Published: 2020
Journal Articles

Phase II Study of Midostaurin + Chemotherapy in Pediatric Patients with Untreated, Newly Diagnosed, FLT3 -Mutated Acute Myeloid Leukemia (AML)

Dirk Reinhardt, MD, Christian Michel Zwaan, Albert Hoenekopp, Julie Niolat, Sophie Ifrah, Florence Noel-Baron, Franco Locatelli, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3835.
https://doi.org/10.1182/blood-2019-128043
Published: 2019
Journal Articles

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of MBG453 Added to Hypomethylating Agents (HMAs) in Patients (pts) with Intermediate, High, or Very High Risk Myelodysplastic Syndrome (MDS): Stimulus-MDS1

Amer M Zeidan, MD, Yasushi Miyazaki, MD PhD, Uwe Platzbecker, Kamel Malek, Julie Niolat, Flavia Kiertsman, Pierre Fenaux, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4259.
https://doi.org/10.1182/blood-2019-127041
Published: 2019